Cosmo Pharmaceuticals N.V. (SWX:COPN)
62.20
-1.60 (-2.51%)
At close: Nov 28, 2025
Cosmo Pharmaceuticals Revenue
Cosmo Pharmaceuticals had revenue of 51.72M EUR in the half year ending June 30, 2025, with 18.46% growth. This brings the company's revenue in the last twelve months to 182.27M, down -1.66% year-over-year. In the year 2024, Cosmo Pharmaceuticals had annual revenue of 266.79M with 187.55% growth.
Revenue (ttm)
182.27M EUR
Revenue Growth
-1.66%
P/S Ratio
5.82
Revenue / Employee
566.41K EUR
Employees
322
Market Cap
991.40M CHF
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 266.79M | 174.01M | 187.55% |
| Dec 31, 2023 | 92.78M | -9.31M | -9.12% |
| Dec 31, 2022 | 102.09M | 37.02M | 56.88% |
| Dec 31, 2021 | 65.07M | 4.13M | 6.77% |
| Dec 31, 2020 | 60.95M | -1.55M | -2.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 44.95B |
| Sandoz Group AG | 8.42B |
| Alcon | 8.12B |
| Lonza Group AG | 7.09B |
| Galenica AG | 4.03B |
| Sonova Holding AG | 3.85B |
| Galderma Group AG | 3.73B |
Cosmo Pharmaceuticals News
- 5 weeks ago - EU Approves Cosmo Pharma' Winlevi For Acne Treatment In Adults And Adolescents - Nasdaq
- 3 months ago - Winlevi Acne Cream Secures EU Drug Panel Support in Reversal for Cosmo - Financial Post
- 8 months ago - Cosmo Pharmaceuticals ernennt neuen Chief Legal Counsel - Cash
- 9 months ago - Cosmo Pharmaceuticals reports FY results - Seeking Alpha
- 9 months ago - Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and ... - GuruFocus
- 9 months ago - Full Year 2024 Cosmo Pharmaceuticals NV Earnings Call Transcript - GuruFocus
- 11 months ago - Cosmo Pharmaceuticals estimates 186% Y/Y growth in 2024 revenue - Seeking Alpha
- 1 year ago - Cosmo Pharmaceuticals gets new finance chief - Seeking Alpha